Current Status and Development of Vaccines and Other Biologics for Human Rabies Prevention
- 22 January 2016
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Vaccines
- Vol. 15 (6), 731-749
- https://doi.org/10.1586/14760584.2016.1140040
Abstract
Rabies is a neglected viral zoonosis with the highest case fatality of any infectious disease. Pasteur’s historical accomplishments during the late 19th century began the process of human vaccine development, continuing to evolve into the 21st century. Over the past 35 years, great improvements occurred in the production of potent tissue culture vaccines and the gradual removal from the market of unsafe nerve tissue products. Timely and appropriate administration of modern biologics virtually assures survivorship, even after severe exposures. Nevertheless, in the developing world, if not provided for free nationally, the cost of a single course of human prophylaxis exceeds the average monthly wage of the common worker. Beyond traditional approaches, recombinant, sub-unit and other novel methods are underway to improve the availability of safe, effective and more affordable rabies biologics.Keywords
This publication has 106 references indexed in Scilit:
- Production, characterization, and antigen specificity of recombinant 62‐71‐3, a candidate monoclonal antibody for rabies prophylaxis in humansThe FASEB Journal, 2013
- Protective Vaccine-Induced CD4+T Cell-Independent B Cell Responses against Rabies InfectionJournal of Virology, 2012
- The Blueprint for Rabies Prevention and Control: A Novel Operational Toolkit for Rabies EliminationPLoS Neglected Tropical Diseases, 2012
- Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in ManScience Translational Medicine, 2012
- Ambivalent Role of the Innate Immune Response in Rabies Virus PathogenesisJournal of Virology, 2011
- Rabies Virus Expressing Dendritic Cell-Activating Molecules Enhances the Innate and Adaptive Immune Response to VaccinationJournal of Virology, 2011
- Monoclonal antibody-based therapies for microbial diseasesVaccine, 2009
- Replication‐Deficient Rabies Virus–Based Vaccines Are Safe and Immunogenic in Mice and Nonhuman PrimatesThe Journal of Infectious Diseases, 2009
- The Glycoprotein and the Matrix Protein of Rabies Virus Affect Pathogenicity by Regulating Viral Replication and Facilitating Cell-to-Cell SpreadJournal of Virology, 2008
- Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccinesBlood, 2007